Clinical Rheumatology

, Volume 36, Issue 10, pp 2169–2178 | Cite as

Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series

  • Manuel Martínez-LavínEmail author
  • Luis Amezcua-Guerra
Review Article


This article critically reviews HPV vaccine serious adverse events described in pre-licensure randomized trials and in post-marketing case series. HPV vaccine randomized trials were identified in PubMed. Safety data were extracted. Post-marketing case series describing HPV immunization adverse events were reviewed. Most HPV vaccine randomized trials did not use inert placebo in the control group. Two of the largest randomized trials found significantly more severe adverse events in the tested HPV vaccine arm of the study. Compared to 2871 women receiving aluminum placebo, the group of 2881 women injected with the bivalent HPV vaccine had more deaths on follow-up (14 vs. 3, p = 0.012). Compared to 7078 girls injected with the 4-valent HPV vaccine, 7071 girls receiving the 9-valent dose had more serious systemic adverse events (3.3 vs. 2.6%, p = 0.01). For the 9-valent dose, our calculated number needed to seriously harm is 140 (95% CI, 79–653). The number needed to vaccinate is 1757 (95% CI, 131 to infinity). Practically, none of the serious adverse events occurring in any arm of both studies were judged to be vaccine-related. Pre-clinical trials, post-marketing case series, and the global drug adverse reaction database (VigiBase) describe similar post-HPV immunization symptom clusters. Two of the largest randomized HPV vaccine trials unveiled more severe adverse events in the tested HPV vaccine arm of the study. Nine-valent HPV vaccine has a worrisome number needed to vaccinate/number needed to harm quotient. Pre-clinical trials and post-marketing case series describe similar post-HPV immunization symptoms.


Adverse events Chronic fatigue syndrome Fibromyalgia HPV vaccine Postural orthostatic tachycardia syndrome 


Compliance with ethical standards




  1. 1.
    HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. Accessed 5 Mar 2017
  2. 2.
  3. 3.
    Richards S, Chalkiadis G, Lakshman R, Buttery JP, Crawford NW (2012) Complex regional pain syndrome following immunisation. Arch Dis Child 97:913–915CrossRefPubMedGoogle Scholar
  4. 4.
    Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y (2013) Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol 70:309–316CrossRefPubMedGoogle Scholar
  5. 5.
    Kinoshita T, Abe RT, Hineno A, Tsunekawa K, Nakane S, Ikeda S (2014) Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med 53:2185–2200CrossRefPubMedGoogle Scholar
  6. 6.
    Blitshteyn S (2014) Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 21:135–139CrossRefPubMedGoogle Scholar
  7. 7.
    Tomljenovic L, Colafrancesco S, Perricone C, Shoenfeld Y (2014) Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the “autoimmune/auto-inflammatory syndrome induced by adjuvants”: case report and literature review. J Investig Med High Impact Case Rep 2:2324709614527812PubMedPubMedCentralGoogle Scholar
  8. 8.
    Poddighe D, Castelli L, Marseglia GL, Bruni PA (2014) Sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? Immune Res 60:236–246. doi: 10.1007/s12026-014-8575-3 CrossRefGoogle Scholar
  9. 9.
    Little DT, Ward HR (2014) Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice. J Investig Med High Impact Case Rep 4:1–12Google Scholar
  10. 10.
    Brinth L, Theibel AC, Pors K, Mehlsen J (2015) Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J 62:A5064PubMedGoogle Scholar
  11. 11.
    Martínez-Lavín M, Martínez-Martínez LA, Reyes-Loyola P (2015) HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol 34:1981–1983CrossRefPubMedGoogle Scholar
  12. 12.
    Hendrickson JE, Tormey CA (2016) Human papilloma virus vaccination and dysautonomia: considerations for autoantibody evaluation and HLA typing. Vaccine 34:4468CrossRefPubMedGoogle Scholar
  13. 13.
    Palmieri B, Poddighe D, Vadalà M, Laurino C, Carnovale C, Clementi E (2017) Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res 65:106–116CrossRefPubMedGoogle Scholar
  14. 14.
    Kafaie J, Kim M, Krause E (2016) Small fiber neuropathy following vaccination. J Clin Neuromuscul Dis 18:37–40CrossRefPubMedGoogle Scholar
  15. 15.
  16. 16.
    Food and Drug Administration. Approved products. Human papillomavirus vaccine. Available at: Accessed 2 May 2017
  17. 17.
    Food and Drug Administration. Safety Medwatch. Available at: Accessed 16 Apr 2017
  18. 18.
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765CrossRefPubMedGoogle Scholar
  19. 19.
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278CrossRefPubMedGoogle Scholar
  20. 20.
    Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E (2007) Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26:201–209CrossRefPubMedGoogle Scholar
  21. 21.
    Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943CrossRefPubMedGoogle Scholar
  22. 22.
    Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373:1949–1957CrossRefPubMedGoogle Scholar
  23. 23.
    Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301–314CrossRefPubMedGoogle Scholar
  24. 24.
    Medina DM, Valencia A, de Velasquez A, Huang LM, Prymula R, García-Sicilia J, Rombo L, David MP, Descamps D, Hardt K, Dubin G (2010) Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health 46:414–421CrossRefPubMedGoogle Scholar
  25. 25.
    Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, Descamps DJ, Bock H (2010) Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 36:123–132CrossRefPubMedGoogle Scholar
  26. 26.
    Ngan HY, Cheung AN, Tam KF, Chan KK, Tang HW, Bi D, Descamps D, Bock HL (2010) Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J 16:171–179PubMedGoogle Scholar
  27. 27.
    Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D (2011) Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364:401–411CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yoshikawa H, Ebihara K, Tanaka Y, Noda K (2013) Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci 104:465–472CrossRefPubMedGoogle Scholar
  29. 29.
    Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, Stapleton JT, Martens M, Quint W, David MP, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G (2014) Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 84:2213–2227CrossRefGoogle Scholar
  30. 30.
    Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:711–723CrossRefPubMedGoogle Scholar
  31. 31.
    Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin MA (2015) Randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls. Pediatr Infect Dis J 34:992–998CrossRefPubMedGoogle Scholar
  32. 32.
    Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A (2015) Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine 33:6855–6864CrossRefPubMedGoogle Scholar
  33. 33.
    Van Damme P, Meijer CJ, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M (2016) A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine 34:4205–4212CrossRefPubMedGoogle Scholar
  34. 34.
    Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G (2009) Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 5:332–340CrossRefPubMedGoogle Scholar
  35. 35.
    Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, TerHarmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YK, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WG, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F (2016) Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis 16:1154–1168CrossRefPubMedGoogle Scholar
  36. 36.
    Martínez-Lavín M (2017) Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial. Clin Rheumatol 36:975CrossRefPubMedGoogle Scholar
  37. 37.
    Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P (2013) Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine 31:4961–4967CrossRefPubMedGoogle Scholar
  38. 38.
    Rodríguez-Galán MA, Pérez-Vilar S, Díez-Domingo J, Tuells J, Gomar-Fayos J, Morales-Olivas F, Pastor-Villalba E (2014) Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011). An Pediatr (Barc) 81:303–309CrossRefGoogle Scholar
  39. 39.
    Liu XC, Bell CA, Simmonds KA, Svenson LW, Russell ML (2016) Adverse events following HPV vaccination, Alberta 2006-2014. Vaccine 34:1800–1805CrossRefPubMedGoogle Scholar
  40. 40.
    Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, Cheetham TC, Liaw KL, Takhar H, Jacobsen SJ (2012) Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 166:1140–1148CrossRefPubMedGoogle Scholar
  41. 41.
    Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A (2013) Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 347:f5906CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Setiawan D, Luttjeboer J, Pouwels KB, Wilschut JC, Postma MJ (2017) Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis. Jpn J Clin Oncol 47:265–276PubMedGoogle Scholar
  43. 43.
    Šubelj M, Učakar V, Kraigher A, Klavs I (2016) Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013. Euro Surveill. doi: 10.2807/1560-7917.ES.2016.21.14.30187
  44. 44.
    Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN (2017) Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase. Drug Saf 40:81–90CrossRefPubMedGoogle Scholar
  45. 45.
    Exley C, Siesjö P, Eriksson H (2010) The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol 31:103–109CrossRefPubMedGoogle Scholar
  46. 46.
    Awate S, Babiuk LA, Mutwiri G (2013) Mechanisms of action of adjuvants. Front Immunol 4:114CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Shoenfeld Y, Agmon-Levin N (2011) ‘ASIA’—autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 36:4–8CrossRefPubMedGoogle Scholar
  48. 48.
    Rigolet M, Aouizerate J, Couette M, Ragunathan-Thangarajah N, Aoun-Sebaiti M, Gherardi RK, Cadusseau J, Authier FJ (2014) Clinical features in patients with long-lasting macrophagic myofasciitis. Front Neurol 5:230CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    de Mos M et al (2007) The incidence of complex regional pain syndrome: a population-based study. Pain 129:12–20CrossRefPubMedGoogle Scholar
  50. 50.
    Del Piñal F (2014) Editorial. I have a dream ... reflex sympathetic dystrophy (RSD or Complex Regional Pain Syndrome - CRPS I) does not exist. J Hand Surg Eur 38:595–597CrossRefGoogle Scholar
  51. 51.
    Martínez-Lavin M (2015) Human papillomavirus vaccination syndrome—small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol 34:1165–1169CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  1. 1.Rheumatology DepartmentNational Institute of CardiologyMexico CityMexico
  2. 2.Immunology DepartmentNational Institute of CardiologyMexico CityMexico

Personalised recommendations